Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis
- PMID: 24299112
- DOI: 10.1111/1471-0528.12460
Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis
Abstract
Objective: To undertake a cost-effectiveness analysis that compares positron emission tomography - computed tomography (PET-CT) imaging plus standard practice with standard practice alone in the diagnosis of recurrent or persistent cervical cancer during routine surveillance and follow-up of women who have previously been diagnosed and treated.
Design: Model-based economic evaluation using data from a systematic review, supplemented with data from other sources, and taking a UK National Health Service (NHS) perspective.
Setting: Secondary Care in England.
Population: Women at least 3 months after the completion of treatment, with either recurrent or persistent cervical cancer.
Methods: A state transition (Markov) model was developed using TreeAge Pro 2011. The structure of the model was informed by the reviews of the trials and clinical input. In the model, two diagnostic strategies were examined. A one-way sensitivity analysis, probabilistic sensitivity analysis, and a value of information analysis were also carried out.
Main outcome measures: Cost-effectiveness based on incremental cost per quality-adjusted life year (QALY).
Results: Adding PET-CT to the current treatment strategy of clinical examination and scanning [magnetic resonance imaging (MRI) and/or CT scan] during the routine surveillance and follow-up of women with recurrent or persistent cervical cancer is significantly more costly, with only a minimal increase in effectiveness. The incremental cost-effectiveness ratio (ICER) for the strategy of PET-CT as an adjunct to the standard treatment strategy that included clinical examination, MRI, and/or CT scan, compared with the usual treatment alone, was over £1 million per QALY.
Conclusion: The results of the current analysis suggest that use of PET-CT in the diagnosis of recurrent or persistent cervical cancer is not cost-effective. Current guidelines recommending imaging using PET-CT as a diagnostic or surveillance tool need to be reconsidered in light of these results. This study did not specifically investigate the use of PET-CT in women with symptoms and radiological suspicion of recurrence where exenteration was considered. More research in that specific area is required.
Keywords: Cervical cancer; decision modelling economic evaluation; systematic review.
© 2013 Royal College of Obstetricians and Gynaecologists.
Similar articles
-
Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.J Clin Oncol. 2015 May 1;33(13):1467-74. doi: 10.1200/JCO.2014.58.5729. Epub 2015 Mar 30. J Clin Oncol. 2015. PMID: 25823735
-
Cost-effectiveness of para-aortic lymphadenectomy before chemoradiotherapy in locally advanced cervical cancer.J Gynecol Oncol. 2015 Jul;26(3):171-8. doi: 10.3802/jgo.2015.26.3.171. Epub 2015 Apr 17. J Gynecol Oncol. 2015. PMID: 25925292 Free PMC article.
-
Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation.BJOG. 2014 Mar;121(4):398-407. doi: 10.1111/1471-0528.12488. Epub 2013 Dec 3. BJOG. 2014. PMID: 24299154 Review.
-
Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer?Int J Gynecol Cancer. 2016 Jun;26(5):944-50. doi: 10.1097/IGC.0000000000000705. Int J Gynecol Cancer. 2016. PMID: 27051057
-
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.J Manag Care Pharm. 2010 Apr;16(3):217-30. doi: 10.18553/jmcp.2010.16.3.217. J Manag Care Pharm. 2010. PMID: 20331326 Free PMC article. Review.
Cited by
-
Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma-A Cost-Effectiveness Analysis.Cancers (Basel). 2020 Aug 27;12(9):2432. doi: 10.3390/cancers12092432. Cancers (Basel). 2020. PMID: 32867107 Free PMC article.
-
Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study.Front Oncol. 2020 Dec 7;10:591253. doi: 10.3389/fonc.2020.591253. eCollection 2020. Front Oncol. 2020. PMID: 33365270 Free PMC article.
-
[18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer.PET Clin. 2018 Apr;13(2):165-177. doi: 10.1016/j.cpet.2017.11.004. Epub 2018 Feb 3. PET Clin. 2018. PMID: 29482748 Free PMC article. Review.
-
Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients.J Nucl Med. 2017 May;58(5):737-743. doi: 10.2967/jnumed.116.183111. Epub 2016 Nov 3. J Nucl Med. 2017. PMID: 27811123 Free PMC article.
-
Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.Br J Radiol. 2017 Mar;90(1071):20160764. doi: 10.1259/bjr.20160764. Epub 2017 Jan 30. Br J Radiol. 2017. PMID: 28008773 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical